Open access
Jul 2026
CRISPR-mediated Correction of Oncogenic AS-NMD in Splicing Factor Mutant Cancer
The CRISPR strategy shows compelling evidence as a therapeutic approach targeting PE in cancer and other human diseases as well as the preferential advantages of CRISPR over the antisense technology recently developed targeting the PE of EZH2.
Preeti Nagar, Md Rafikul Islam, Nirjhor Anuvob Rahman et al.
· bioRxiv · 0 citations